Clinical trials: Recurrent Vulvovaginal Candidiasis
Recurrent Vulvovaginal Candidiasis
Effect of a Lactobacillus Strain on the Prevention of Recurrent Vaginal Candidiasis
The objective of this study is to evaluate the efficacy of the consumption of the one probiotic strain in the prevention of new vaginal candidiasis events in women with recurrent vaginal candidiasis.
- Trial name
- NCT04639544
- Testing
- Lactobacillus strain
- Where
- Spain
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Biosearch S.A.
Candidiasis, Vulvovaginal, Recurrent Candidiasis of Vagina
Fluconazol Versus Medical Honey in the Treatment of Recurrent Vulvovaginal Candidiasis
The purpose of this study is to compare the efficacy of Flucanzol versus L-mesitran in the treatment of patients with recurrent vulvovaginal candidiasis. The investigator will look at vaginal swabs after 1, 6 and 12 months.
- Trial name
- NCT04626258
- Testing
- Fluconazole, L-Mesitran
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Vulvovaginal Candidiasis, Genital, Laser Therapy
A Protocol for the Role of Fractional CO2 Laser in Consolidation Treatment of Recurrent Vulvovaginal Candidiasis
Background: Recurrent vulvovaginal candidiasis (RVVC) is a common obstinate vulvovaginal inflammation in gynecology. At present, the pathogenesis of RVVC is not clear.
- Trial name
- NCT04292704
- Testing
- the fractional CO2 laser, Clotrimazole
- Where
- China
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital of Wenzhou Medical University
Vulvovaginal Candidiasis
Effect of a Multi-strain Probiotic on Recurrent Vulvovaginal Candidiasis
This study evaluates the effect of a multi-strain probiotic on the risk of recurrence and severity of symptoms in females with recurrent vulvovaginal candidiasis (R-VVC).
- Trial name
- PROVELIA (NCT06480604)
- Testing
- Probiotic
- Where
- 6 sites in India
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- The Archer-Daniels-Midland Company
Recurrent Vulvovaginal Candidiasis
Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection
Pevion Biotech develops a state-of-the-art vaccine against recurrent vulvovaginal candidiasis (RVVC) caused by the pathogenic form of Candida albicans especially in pre-menopausal women of childbearing age with a history of…
- Trial name
- NCT01067131
- Testing
- PEV7C1, PEV7C9, PEV7B2
- Where
- 2 sites in Switzerland
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Pevion Biotech Ltd